• Explore /
  • Poster
  • / First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).

First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).

Abstract Poster

Authors

Nazli Dizman

Nazli Dizman

City of Hope Comprehensive Cancer Center, Duarte, CA

Nazli Dizman , Joann Hsu , John D Gillece , Megan Folkerts , Lauren J Reining , Paulo Gustavo Bergerot , Luis A Meza , Zeynep Busra Zengin , Ramya Muddasani , Neal Chawla , Misagh Karimi , Jeffrey M. Trent , Sarah K Highlander , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Translational Research

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 337)

DOI

10.1200/JCO.2021.39.6_suppl.337

Abstract #

337

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Matt D. Galsky

Poster

2014 Genitourinary Cancers Symposium

Are regional funding decisions resticting pharmaceutical research and development in metastatic renal cell carcinoma (mRCC)?

Are regional funding decisions resticting pharmaceutical research and development in metastatic renal cell carcinoma (mRCC)?

First Author: Henry Jacob Conter

First Author: Makoto Nishio

First Author: William A. Hall